CA53946V2066
© ACCESSWIRE
13.01.2026
LOBE
LISTED
CSE
Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors
News Preview
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 13, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing therapies for diseases with significant unmet medical needs, today announced the appointment of Mr. Nick Kar...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.01.2026
LOBE
LISTED
CSE
Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy
News Preview
Balance Sheet and Sharpened Strategy VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 8, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported audited financial results for the fisca...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.01.2026
LOBE
LISTED
CSE
Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition
News Preview
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported audited financial results for the fiscal year ended August 31, 2025 ("FY2025&...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© ACCESSWIRE
23.10.2025
LOBE
LISTED
CSE
Lobe Sciences Completes Debt Settlement to Improve Balance Sheet
News Preview
VANCOUVER, BC / ACCESS Newswire / October 23, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops novel therapies through a scalable model of shared services, global teams, and outsourced infrastructure. The Company creates intellectual prop...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESSWIRE
09.10.2025
LOBE
LISTED
CSE
Lobe Sciences Improves Balance Sheet
News Preview
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / October 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops novel therapies through a scalable model of shared services, global teams, and outsourced infrastructure. The Company creates inte...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
09.09.2025
LOBE
LISTED
CSE
Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025
News Preview
VANCOUVER, B.C. / ACCESS Newswire / September 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming Cluster...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.09.2025
LOBE
LISTED
CSE
Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors
News Preview
VANCOUVER, BC / ACCESS Newswire / September 8, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce the appointment of Mr. Marco Mastr...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.08.2025
LOBE
LISTED
CSE
Lobe Sciences Announces the Closing of the Previously Announced Private Placement
News Preview
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 14, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.07.2025
LOBE
LISTED
CSE
Lobe Sciences Announces $341,425 CAD Private Placement for General Corporate Purposes
News Preview
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.07.2025
LOBE
LISTED
CSE
Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory
News Preview
VANCOUVER, BC / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases, today announced its formal engagement with ArcStone Securities and Investments Corp. ("ArcStone"), a capital markets advisory firm.Under...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
16.07.2025
LOBE
LISTED
CSE
Lobe Sciences Ltd. Announces Debt Settlement
News Preview
VANCOUVER, BC / ACCESS Newswire / July 16, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company committed to developing innovative treatments for underserved diseases, today announced that it has settled an outstanding debt of CAD$11,596.22 owed to Gibbsons P.C. for legal services previously provided to the Com...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.07.2025
LOBE
LISTED
CSE
Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease
News Preview
European Unitary Patent EP4117446 Validated - Lobe Sciences secures patent protection in 17 EU member states for its DHA and egg yolk-based composition designed to manage Sickle Cell Disease.Covers Altemia(R) Medical Food Formula - The patented composition underpins Altemia(R), a physician-supervised medical food formulated to address long-chain fa...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESSWIRE
17.06.2025
LOBE
LISTED
CSE
Lobe Sciences Moves Forward with Development of Conjugated Psilocin(TM) Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals
News Preview
New subsidiary, Cynaptec Pharmaceuticals, established to hold global rights to Conjugated Psilocin™$6 million investment in Cynaptec Pharmaceuticals secured to advance research and early-stage clinical trials for chronic cluster headaches and addictionOption for an additional $20 million investment in Cynaptec Pharmaceuticals to support Phase...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
03.06.2025
LOBE
LISTED
CSE
Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth
News Preview
Lobe Sciences Ltd. has appointed Mr. Yong Yao as Chief Financial Officer and Executive Vice President, effective June 1, 2025, to lead the company's financial strategy during its next phase of growth.Mr. Yao brings over 25 years of experience across finance and biotech, with executive roles at companies such as Mountain Valley MD and global firms l...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.04.2025
LOBE
LISTED
CSE
Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin(TM)
News Preview
Private Placement of US$6 Million to fund additional pre-clinical research, Phase 1 and Phase 2a clinical studiesUS$20 Million additional option included in Private Placement to fund the Phase 3 clinical program in chronic cluster headacheLobe creates Cynaptec Pharmaceuticals, Inc. which will own and develop Conjugated Psilocin TM VANCOUVER, BC / A...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
04.04.2025
LOBE
LISTED
CSE
Lobe Sciences Provides Corporate Update
News Preview
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / April 4, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a commercial stage biopharmaceutical company focused on developing products using lipid technology to treat diseases with significant unmet medical needs is providing a corporate updat...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
LOBE
LISTED
CSE
Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™
News Preview
Lobe Sciences, Ltd. ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma, Inc. (“Alera” or “Alera Pharma”), biopharmaceutical companies focused on developing products to treat diseases with significant unmet medical needs, today announce that a second patent allowance for Conjugated Psilocin™ has been received. The paten...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2024
LOBE
LISTED
CSE
Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™
News Preview
Lobe Sciences Ltd ("Lobe" or the "Company") (CSE: LOBE), (OTCQB: LOBEF), a biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce the appointment of Enclave Capital and Peak Asset Management (the “Bankers”) to begin the process of raising funds to advance the developme...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2024
LOBE
LISTED
CSE
Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™
News Preview
Lobe Sciences, Ltd. (“Lobe Sciences” or the “Company”) (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma (“Alera or Alera Pharma”), biopharmaceutical companies focused on developing products to treat diseases with significant unmet medical needs, today announce the issuance by the United States Patent and Trademark Office (USPTO) of U.S. Patent number...
Themefolio
Profiler
Peergroup
© BusinessWire
16.08.2024
LOBE
LISTED
CSE
Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.
News Preview
Lobe Sciences, Ltd ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF), a biopharmaceutical company focused on developing products to treat diseases with unmet medical needs, today announced that is has formed a wholly owned U.S. subsidiary named Alera Pharma, Inc. (Alera). Alera will be assigned the intellectual property rights focused...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2024
LOBE
LISTED
CSE
Lobe Sciences Announces Appointment of a New Board of Directors and Executive Management Team
News Preview
Lobe Sciences Ltd ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF), a biopharmaceutical company focused on developing products to treat diseases with unmet medical needs, today announced that a new board of directors (“Board”) has been elected at the Company’s annual general meeting, with shareholders electing the three previously an...
Themefolio
Profiler
Peergroup
© Newsfile
01.07.2023
LOBE
LISTED
CSE
Lobe Sciences Announces Additional Details Regarding the Acquisition of Altemia(TM) & Company
News Preview
Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and Generate Commercial Revenue in the Second Half of 2023Acquisition also Includes an International License Agreement With Double Digit Royalty and...
Themefolio
Profiler
Peergroup
© Newsfile
21.04.2023
LOBE
LISTED
CSE
Lobe Sciences, Ltd. Provides Update on Vitamind
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today provides an update on its acquisition of the Vitamind Brand and inte...
Themefolio
Profiler
Peergroup
© Newsfile
18.04.2023
LOBE
LISTED
CSE
Lobe Sciences, Ltd. Announces the Acquisition of Altemia(TM) & Company
News Preview
Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and Generate Commercial Revenue in the Second Half of 2023Acquisition also Includes an International License Agreement With Double Digit Royalty and...
Themefolio
Profiler
Peergroup
© Newsfile
04.04.2023
LOBE
LISTED
CSE
Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced that Philip Young, CEO and Executive Chairman, wi...
Themefolio
Profiler
Peergroup
© Newsfile
22.03.2023
LOBE
LISTED
CSE
Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130
News Preview
Dosing In Human Clinical Trial To Commence Within WeeksVancouver, British Columbia--(Newsfile Corp. - March 22, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced tha...
Themefolio
Profiler
Peergroup
© Newsfile
21.02.2023
LOBE
LISTED
CSE
Lobe Sciences Ltd. Announces Exclusive Collaboration with Quality Chemical Laboratories LLC
News Preview
Quality Chemical Laboratories LLC ("QCL") has developed a synthetic pathway for psilocybin, psilocin and psilocin analogues exclusively for Lobe SciencesQCL agrees to supply Lobe Sciences research and commercial quantities of two new chemical entities, L-130 and L-131 under an exclusive arrangement Lobe Sciences Ltd. and QCL have entered into an ag...
Themefolio
Profiler
Peergroup
© Newsfile
10.02.2023
LOBE
LISTED
CSE
Lobe Sciences, Ltd. Announces USD$250,000 Convertible Note Financing and Warrant Issuance
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 10, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient-focused psychedelic-derived medicines for neurologic and brain disease today announced a financing in the amount of US...
Themefolio
Profiler
Peergroup
© Newsfile
06.02.2023
LOBE
LISTED
CSE
Lobe Sciences Congratulates Australia for Becoming the First Nation to Approve the Medicinal Use of Psilocybin and MDMA
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today congratulated the people of Australia for the decision by...
Themefolio
Profiler
Peergroup
© Newsfile
26.01.2023
LOBE
LISTED
CSE
Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache
News Preview
Dr. Lauren R. Natbony to be Principal InvestigatorVancouver, British Columbia--(Newsfile Corp. - January 26, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient-focused psychedelic-derived medicines for neurologic and brain diseas...
Themefolio
Profiler
Peergroup
© Newsfile
23.01.2023
LOBE
LISTED
CSE
Lobe Sciences Board of Directors Elects to Receive Shares in Lieu of Cash for All Board Fees
News Preview
Endorsement underscores transition into a fully integrated biotechnology companyVancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic an...
Themefolio
Profiler
Peergroup
© Newsfile
18.01.2023
LOBE
LISTED
CSE
Lobe Sciences Provides Update For 2023 Milestones
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient focused psychedelic derived medicines for neurologic and brain disease today announced an updated overview for 2023.Mr....
Themefolio
Profiler
Peergroup
© Newsfile
30.11.2022
LOBE
LISTED
CSE
Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 30, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced an update for its clinical development plans fo...
Themefolio
Profiler
Peergroup
© Newsfile
09.06.2022
LOBE
LISTED
CSE
CSE Bulletin: Consolidation - Lobe Sciences Ltd. (LOBE)
News Preview
Toronto, Ontario--(Newsfile Corp. - Le 9 juin/June 2022) - Lobe Sciences Ltd. (the "Issuer") has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every six (6) pre-consolidated common shares. As a result, the outstanding common shares of the Issuer w...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
